A phase 1b study evaluating the safety and preliminary efficacy of berzosertib in combination with gemcitabine in patients with advanced non-small cell lung cancer.
Saved in:
| Title: | A phase 1b study evaluating the safety and preliminary efficacy of berzosertib in combination with gemcitabine in patients with advanced non-small cell lung cancer. |
|---|---|
| Authors: | Plummer R; Newcastle University and Northern Centre for Cancer Care, Newcastle Hospitals NHS Trust, Newcastle Upon Tyne, United Kingdom. Electronic address: Ruth.Plummer@newcastle.ac.uk., Dean E; The University of Manchester and The Christie NHS Foundation Trust, Manchester, United Kingdom. Electronic address: Emma.Dean@doctors.org.uk., Arkenau HT; Sarah Cannon Research Institute, London, United Kingdom. Electronic address: Tobias.Arkenau@hcahealthcare.co.uk., Redfern C; Sharp Healthcare, San Diego, CA, United States., Spira AI; Virginia Cancer Specialists Research Institute and US Oncology Research, Fairfax, VA, United States., Melear JM; Texas Oncology, Austin, TX, United States. Electronic address: Jason.Melear@usoncology.com., Chung KY; Prisma Health, Greenville, SC, United States. Electronic address: Ki.Chung@prismahealth.org., Ferrer-Playan J; Ares Trading SA, Eysins, Switzerland, an affiliate of Merck KGaA, Darmstadt, Germany., Goddemeier T; Merck Healthcare KGaA, Darmstadt, Germany., Locatelli G; Merck Healthcare KGaA, Darmstadt, Germany., Dong J; EMD Serono Research & Development Institute, Inc., Billerica, MA, United States., Fleuranceau-Morel P; EMD Serono Research & Development Institute, Inc., Billerica, MA, United States., Diaz-Padilla I; Ares Trading SA, Eysins, Switzerland, an affiliate of Merck KGaA, Darmstadt, Germany., Shapiro GI; Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, United States. Electronic address: Geoffrey_Shapiro@dfci.harvard.edu. |
| Source: | Lung cancer (Amsterdam, Netherlands) [Lung Cancer] 2022 Jan; Vol. 163, pp. 19-26. Date of Electronic Publication: 2021 Dec 01. |
| Publication Type: | Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Elsevier Scientific Publishers Country of Publication: Ireland NLM ID: 8800805 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1872-8332 (Electronic) Linking ISSN: 01695002 NLM ISO Abbreviation: Lung Cancer Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 34894455 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: A phase 1b study evaluating the safety and preliminary efficacy of berzosertib in combination with gemcitabine in patients with advanced non-small cell lung cancer. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Plummer+R%22">Plummer R</searchLink>; Newcastle University and Northern Centre for Cancer Care, Newcastle Hospitals NHS Trust, Newcastle Upon Tyne, United Kingdom. Electronic address: Ruth.Plummer@newcastle.ac.uk.<br /><searchLink fieldCode="AU" term="%22Dean+E%22">Dean E</searchLink>; The University of Manchester and The Christie NHS Foundation Trust, Manchester, United Kingdom. Electronic address: Emma.Dean@doctors.org.uk.<br /><searchLink fieldCode="AU" term="%22Arkenau+HT%22">Arkenau HT</searchLink>; Sarah Cannon Research Institute, London, United Kingdom. Electronic address: Tobias.Arkenau@hcahealthcare.co.uk.<br /><searchLink fieldCode="AU" term="%22Redfern+C%22">Redfern C</searchLink>; Sharp Healthcare, San Diego, CA, United States.<br /><searchLink fieldCode="AU" term="%22Spira+AI%22">Spira AI</searchLink>; Virginia Cancer Specialists Research Institute and US Oncology Research, Fairfax, VA, United States.<br /><searchLink fieldCode="AU" term="%22Melear+JM%22">Melear JM</searchLink>; Texas Oncology, Austin, TX, United States. Electronic address: Jason.Melear@usoncology.com.<br /><searchLink fieldCode="AU" term="%22Chung+KY%22">Chung KY</searchLink>; Prisma Health, Greenville, SC, United States. Electronic address: Ki.Chung@prismahealth.org.<br /><searchLink fieldCode="AU" term="%22Ferrer-Playan+J%22">Ferrer-Playan J</searchLink>; Ares Trading SA, Eysins, Switzerland, an affiliate of Merck KGaA, Darmstadt, Germany.<br /><searchLink fieldCode="AU" term="%22Goddemeier+T%22">Goddemeier T</searchLink>; Merck Healthcare KGaA, Darmstadt, Germany.<br /><searchLink fieldCode="AU" term="%22Locatelli+G%22">Locatelli G</searchLink>; Merck Healthcare KGaA, Darmstadt, Germany.<br /><searchLink fieldCode="AU" term="%22Dong+J%22">Dong J</searchLink>; EMD Serono Research & Development Institute, Inc., Billerica, MA, United States.<br /><searchLink fieldCode="AU" term="%22Fleuranceau-Morel+P%22">Fleuranceau-Morel P</searchLink>; EMD Serono Research & Development Institute, Inc., Billerica, MA, United States.<br /><searchLink fieldCode="AU" term="%22Diaz-Padilla+I%22">Diaz-Padilla I</searchLink>; Ares Trading SA, Eysins, Switzerland, an affiliate of Merck KGaA, Darmstadt, Germany.<br /><searchLink fieldCode="AU" term="%22Shapiro+GI%22">Shapiro GI</searchLink>; Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, United States. Electronic address: Geoffrey&#95;Shapiro@dfci.harvard.edu. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%228800805%22">Lung cancer (Amsterdam, Netherlands)</searchLink> [Lung Cancer] 2022 Jan; Vol. 163, pp. 19-26. <i>Date of Electronic Publication: </i>2021 Dec 01. – Name: TypePub Label: Publication Type Group: TypPub Data: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Elsevier+Scientific+Publishers%22">Elsevier Scientific Publishers </searchLink><i>Country of Publication: </i>Ireland <i>NLM ID: </i>8800805 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1872-8332 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2201695002%22">01695002 </searchLink><i>NLM ISO Abbreviation: </i>Lung Cancer <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=34894455 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1016/j.lungcan.2021.11.011 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 19 Titles: – TitleFull: A phase 1b study evaluating the safety and preliminary efficacy of berzosertib in combination with gemcitabine in patients with advanced non-small cell lung cancer. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Plummer R – PersonEntity: Name: NameFull: Dean E – PersonEntity: Name: NameFull: Arkenau HT – PersonEntity: Name: NameFull: Redfern C – PersonEntity: Name: NameFull: Spira AI – PersonEntity: Name: NameFull: Melear JM – PersonEntity: Name: NameFull: Chung KY – PersonEntity: Name: NameFull: Ferrer-Playan J – PersonEntity: Name: NameFull: Goddemeier T – PersonEntity: Name: NameFull: Locatelli G – PersonEntity: Name: NameFull: Dong J – PersonEntity: Name: NameFull: Fleuranceau-Morel P – PersonEntity: Name: NameFull: Diaz-Padilla I – PersonEntity: Name: NameFull: Shapiro GI IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 01 Text: 2022 Jan Type: published Y: 2022 Identifiers: – Type: issn-electronic Value: 1872-8332 Numbering: – Type: volume Value: 163 Titles: – TitleFull: Lung cancer (Amsterdam, Netherlands) Type: main |
| ResultId | 1 |
